Research graph
References from Case Report: Hematopoietic stem cell transplantation for refractory chronic immune thrombocytopenia in a child. Local targets link to admitted publications; unresolved targets remain external evidence.
American Society of Hematology 2019 guidelines for immune thrombocytopenia
10.1182/bloodadvances.2019000966 · 2019 · External reference
The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia
10.1182/bloodadvances.2023012541 · 2024 · External reference
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review
10.12701/jyms.2022.00745 · 2023 · External reference
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment
10.1182/blood.2019003599 · 2020 · External reference
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome
10.1002/ajh.27337 · 2024 · External reference
Novel therapeutics and future directions for refractory immune thrombocytopenia
10.1111/bjh.19078 · 2023 · External reference
What is in a name: defining pediatric refractory ITP
10.1182/bloodadvances.2024012707 · 2024 · External reference
Chronic refractory immune thrombocytopenia in adolescents and young adults
10.1111/bjh.19081 · 2023 · External reference
How I treat refractory immune thrombocytopenia
10.1182/blood-2016-03-603365 · 2016 · External reference
Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom
10.1111/vox.12314 · 2016 · External reference
Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias
10.1080/08916930802198436 · 2008 · External reference
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
10.1038/bmt.2011.185 · 2012 · External reference
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
10.1007/s00277-022-04786-y · 2022 · External reference
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial
10.1038/s41392-024-01793-5 · 2024 · External reference
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia
10.1111/j.1365-2141.2004.04978.x · 2004 · External reference
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research
10.1016/j.bbmt.2012.06.003 · 2012 · External reference
Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia
10.1046/j.1365-2141.1997.3553169.x · 1997 · External reference
Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura
10.1016/s0140-6736(05)61187-7 · 1997 · External reference
High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia
10.1182/blood-2001-12-0171 · 2003 · External reference
Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children
10.1016/j.bbmt.2012.12.008 · 2013 · External reference
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: A 2023 update
10.1016/j.jtct.2023.12.001 · 2024 · External reference
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial
10.1007/s00277-024-05826-5 · 2024 · External reference
